Universal posttransplant cyclophosphamide after allogeneic transplant, a retrospective single institution study

Keyphrases

• Allogeneic Transplant 100%
• Single Institution Study 100%
• Post-transplantation Cyclophosphamide (PTCy) 100%
• Non-relapse Mortality 60%
• Black Men 40%
• Haploidentical 40%
• Black Race 40%
• Selection Algorithm 40%
• Donor Selection 40%
• Disease Risk Prediction 40%
• Number of Patients 20%
• Immunosuppression 20%
• Overall Survival 20%
• Graft-versus-host Disease (GvHD) 20%
• Multivariate Analysis 20%
• Female-to-male 20%
• Engraftment 20%
• Mitigation Strategies 20%
• Disease-free 20%
• Haploidentical Donor 20%
• Donor-recipient Matching 20%
• Unrelated Donor 20%
• Male Donor 20%
• First 100 Days 20%
• Unrelated Donor Transplantation 20%
• Graft-versus-host Disease Prophylaxis 20%
• Matched Sibling 20%
• Matched Donors 20%
• Alternative Donor Transplant 20%
• Engraftment Time 20%

Immunology and Microbiology

• Cyclophosphamide 100%
• Graft-Versus-Host Disease 66%
• Engraftment 66%
• Donor Selection 66%
• Immunosuppression 33%
• Overall Survival 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Cyclophosphamide 100%
• Diseases 100%
• Graft Versus Host Reaction 66%
• Overall Survival 33%